UC Davis

UC Davis Previously Published Works

Title

Structure of human GABA_B receptor in an inactive state.

Permalink

<https://escholarship.org/uc/item/0n8972fx>

Journal

Nature, 584(7820)

ISSN

0028-0836

Authors

Park, Jinseo
Fu, Ziao
Frangaj, Aurel
et al.

Publication Date

2020-08-01

DOI

10.1038/s41586-020-2452-0

Peer reviewed

Published in final edited form as:

Nature. 2020 August ; 584(7820): 304–309. doi:10.1038/s41586-020-2452-0.

Structure of human GABA_B receptor in an inactive state

Jinseo Park^{1,19}, Ziao Fu^{2,19}, Aurel Frangaj^{1,19}, Jonathan Liu^{1,19}, Lidia Mosyak^{1,19}, Tong Shen^{3,19}, Vesna N. Slavkovich⁴, Kimberly M. Ray¹, Jaume Taura⁵, Baohua Cao¹, Yong Geng^{1,6}, Hao Zuo¹, Yongjun Kou⁶, Robert Grassucci², Shaoxia Chen⁷, Zheng Liu², Xin Lin^{8,14}, Justin P. Williams⁹, William J. Rice¹⁰, Edward T. Eng¹⁰, Rick K. Huang¹¹, Rajesh K. Soni¹², Brian Kloss¹³, Zhiheng Yu¹¹, Jonathan A. Javitch^{1,8,9,14}, Wayne A. Hendrickson^{2,9,13}, Paul A. Slesinger⁵, Matthias Quick^{8,14}, Joseph Graziano⁴, Hongtao Yu¹⁵, Oliver Fiehn³, Oliver B. Clarke^{9,16,*}, Joachim Frank^{2,17,*}, Qing R. Fan^{1,18,*}

¹Department of Pharmacology, Columbia University, New York, NY, USA.

²Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.

³NIH West Coast Metabolomics Center, University of California Davis, CA, USA.

⁴Department of Environmental Health Sciences, Columbia University, New York, NY, USA.

⁵Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

⁶Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

⁷MRC Laboratory of Molecular Biology, Cambridge, UK.

⁸Department of Psychiatry, Columbia University, New York, NY, USA.

⁹Department of Physiology and Cellular Biophysics, Columbia University, New York, NY, USA.

¹⁰National Resource for Automated Molecular Microscopy, Simons Electron Microscopy Center, New York Structural Biology Center, New York, NY, USA.

¹¹Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

*Correspondence and request for materials should be addressed to oc2188@cumc.columbia.edu (O.B.C.);

jf2192@cumc.columbia.edu (J.F.); qf13@cumc.columbia.edu (Q.R.F.).

Author contributions: J.P., J.L., Q.R.F. and K.M.R. cultured cells and purified protein; Z.J.F. and A.F. prepared cryo-EM grids; Z.F., A.F., Q.R.F. and O.B.C. collected cryo-EM data; Z.J.F. and A.F. performed initial image processing; O.B.C. processed cryo-EM data to high resolution; L.M. and Q.R.F. built and refined models; Q.R.F., L.M., A.F., J.P. and Z.F. analyzed structures; T.S. and O.F. identified phospholipids and GABA by mass spectrometry; V.N.S. and J.G. conducted elemental analysis; Q.R.F., J.L., J.P., A.F., J.T., X.L. and J.P.W. performed mutagenesis and cell-based functional assay; M.Q. performed and analyzed radioligand binding studies; B.C., Y.G., H.Z., and Y.K. generated expression plasmids and carried out early protein purification trials; R.G., W.R., E.E., R.K.H., Z.Y. assisted with cryo-EM data collection; S.C., Z.L., W.R. and E.E. performed initial cryo-EM characterization; R.K.S. measured molecular mass; B.K. screened detergents; W.A.H. contributed to structural analysis; Q.R.F., P.A.S. and J.A.J. supervised functional analysis; J.F., O.B.C., and H.Y. supervised cryo-EM studies; Q.R.F. and A.F. wrote the paper; T.S., V.N.S., M.Q., Z.F. and R.K.S. contributed methods sections; all authors contributed to the revision; Q.R.F., A.F., J.P., O.B.C., T.S., Z.F., J.L. and M.Q. prepared figures; Q.R.F. conceived and supervised the project.

Competing interests: The authors declare no competing interests.

Extended data is available for this paper.

Supplementary information is available for this paper.

¹²Proteomics Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.

¹³Center on Membrane Protein Production and Analysis, New York Structural Biology Center, New York, NY, USA.

¹⁴Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY, USA.

¹⁵Howard Hughes Medical Institute, Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

¹⁶Department of Anesthesiology and the Irving Institute for Clinical and Translational Research, Columbia University, New York, NY, USA.

¹⁷Department of Biological Sciences, Columbia University, New York, NY, USA.

¹⁸Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.

¹⁹These authors contributed equally to this work.

Abstract

Human GABA_B G protein-coupled receptor (GPCR), a member of the class C family, mediates inhibitory neurotransmission and is implicated in epilepsy, pain, and addiction¹. A unique GPCR known to require heterodimerization for function^{2–6}, its two subunits, GABA_{B1} and GABA_{B2}, are structurally homologous but perform distinct and complementary functions. GABA_{B1} recognizes orthosteric ligand^{7,8}, while GABA_{B2} couples with G protein^{9–14}. Each subunit is characterized by an extracellular Venus flytrap (VFT) module, a descending peptide linker, a seven-helix transmembrane (TM) domain, and a cytoplasmic tail¹⁵. Whereas the VFT heterodimer structure has been resolved¹⁶, the structure of the full-length receptor and its transmembrane signaling mechanism remain unknown. Here we present a near full-length structure of the GABA_B receptor, captured in an inactive state via cryo-electron microscopy (EM). Our structure reveals multiple ligands pre-associated with the receptor, including two large endogenous phospholipids embedded within the TM domains to maintain receptor integrity and modulate receptor function. We also identify a novel heterodimer interface between TM helices 5 and 3 of both subunits, which serves as a signature of the inactive conformation. A unique ‘intersubunit latch’ within this TM interface maintains the inactive state, and its disruption leads to constitutive receptor activity.

Architecture of GABA_B receptor

The heterodimeric human GABA_B receptor was assembled using baculovirus-infected mammalian cells. Each subunit was truncated at the carboxyl terminal end according to the domain boundary of the intracellular coiled-coil¹⁷ to eliminate flexible regions (Supplementary Fig. 1). Upon extraction and purification with detergent (Extended Data Fig. 1a,b; Supplementary Fig. 2), the complex bound radioactive [³H]GABA with a dissociation constant comparable to the GABA affinity reported for native receptors^{3,4,7} (Extended Data Fig. 1c). Functional analysis incorporating a chimeric Gα_{q15} protein and inositol phosphate (IP) assay¹⁸ in mammalian cells showed that agonist baclofen activated the C-terminally truncated and full-length receptor with similar potency and efficacy, indicating that the

deleted regions in the GABA_{B1b} and GABA_{B2} cytoplasmic tails are not required for ligand-mediated G protein activation (Extended Data Fig. 1d).

We determined the structure of the heterodimeric GABA_B receptor by cryo-EM to an overall resolution of 3.3 Å (Extended Data Fig. 2a–e; Supplementary Table 1). The global density map displayed directional anisotropy due to linker flexibility (Extended Data Fig. 2f). Performing local refinement separately on the extracellular (ECD) and TM domains yielded 3.1 Å and 3.4 Å resolution reconstructions, respectively (Extended Data Figs. 2g,h). A composite map combining the ECD and TM reconstructions was used for model building and refinement (Extended Data Fig. 3). By applying three-dimensional variability analysis of the data, we found that the receptor is in dynamic motion, and its functional state corresponds to a continuum of conformations along multiple dimensions (Supplementary Video 1–4).

The heterodimeric GABA_B receptor is assembled by GABA_{B1b} and GABA_{B2} subunits interacting side-by-side while facing opposite directions (Fig. 1a,b; Extended Data Fig. 4). Both the VFT and TM components of the two subunits are related by pseudo two-fold axes. Extracellular and intracellular loops (ECLs and ICLs) that interconnect adjacent helices within each TM are visible in the density map, except for ICL2. The cytoplasmic tail including the coiled-coil domain is disordered, possibly due to its flexible attachment to the TM domain.

The elongated peptide linker joining the VFT to the TM is buttressed through its interaction with a β-hairpin formed by ECL2 (Fig. 1c). ECL2 twists across the linker, forming a united mechanical junction to transmit the conformational changes in the VFT to the TM and vice versa. Additionally, the ECD and TM domains of the receptor spontaneously flex back and forth about the linker, exhibiting the region's intrinsic flexibility (Supplementary Video 1).

Since no ligand was added during protein purification, we expected the receptor to be in an apo form and inactive conformation. To our surprise, we observed multiple ligands bound to the receptor. GABA_{B1b} contains a Ca²⁺ at the interdomain cleft of VFT. In addition, an endogenous phospholipid is bound within the TM pocket of each subunit, with a phosphatidylethanolamine (PE 38:5) in GABA_{B1b}, and a phosphatidylcholine (PC 38:2) in GABA_{B2}. Finally, ten cholesterol or cholesteryl hemisuccinate molecules, which we modeled as cholesterol (Methods), are distributed around the exterior of the TM complex, including two that interface both subunits.

Inactive conformation of GABA_B receptor

The cryo-EM structure of GABA_B receptor occupies an inactive conformation based on its similarity to the known crystal structures of GABA_B VFT in the apo and antagonist-bound states¹⁶. First, the VFT module, composed of LB1 and LB2 domains, adopts an open interdomain conformation in both subunits (Extended Data Fig. 5a,b). Second, while an N-terminal LB1-LB1 dimer interface is present in all functional states, the distinct lack of a heterodimer interface between the membrane-proximal LB2 domains is shared by the near full-length cryo-EM structure and inactive-state VFT structures (Extended Data Fig. 5c,d).

In contrast, a hallmark of the active-state VFT structures is a novel heterodimer interface between LB2 domains, which results from agonist-induced GABA_{B1b} closure¹⁶.

Using conformational variability analysis, we observed that the LB2 domains of both subunits fluctuate by approaching and withdrawing from the central vertical axis of the heterodimer, yet never make contact as in active-state VFT crystal structures (Supplementary Video 2,3). The motion exhibited by the LB2 domains and their associated linkers suggests that the inactive functional state corresponds to an ensemble of conformations, where the separation between the membrane proximal regions falls within a small range around the coordinates of the current structure.

TM heterodimer interface in the inactive state

We identified a novel heterodimer interface between the TM5 and TM3 helices of both subunits, that embodies the signature of the GABA_B inactive conformation (Fig. 2a). A TM5-TM5 contact has previously been detected through crosslinking of the GABA_B receptor¹⁹, but TM dimer interfaces of any kind are yet to be found in other inactive class C GPCRs, including the recent inactive metabotropic glutamate receptor mGlu₅ structure²⁰ (Extended Data Fig. 5e).

Positioned at 30° from the extracellular dimer interface, the TM dimer interactions bury approximately 740 Å² of surface area and exhibit high shape complementarity (Extended Data Fig. 5f). The pair of TM5 helices scissor at their central residues before contacting the transverse TM3 of opposing subunits at their intracellular ends (Fig. 2a). TM5 extracellular ends display conformational variance wherein they approach and withdraw but fail to make contact (Supplementary Video 4). All direct heterodimer interactions occur near the cytoplasmic membrane surface and can be divided into three core layers (I-III) along the helical path of TM5 (Fig. 2a).

The surface layer I caps the extracellular end of the TM heterodimer interface. It is comprised of hydrophobic contacts between four leucine residues of both subunits. The middle layer II lies directly beneath layer I, and consists of three phenylalanine residues packing against one another, as well as their neighboring leucine residues. Both layers solely incorporate TM5 residues.

Layer III, consisting of sections IIIa and IIIb, completes the interface at the intracellular end. IIIa possesses a network of salt-bridges that tether the cytoplasmic ends of GABA_{B1b} and GABA_{B2} TM domains. This critical interaction is mediated by a quartet of charged residues from TM3 and TM5 helices (GABA_{B1b}: His572^{3,55} and Glu673^{5,60}; GABA_{B2}: His579^{3,55} and Glu677^{5,60}) (Supplementary Table 2), a feature we refer to as the 'intersubunit latch' for securing the TM orientation of the two subunits in the inactive conformation. One of the 'intersubunit latch' residues shares nonpolar contacts with a lysine of GABA_{B2} TM5, establishing the accessory site IIIb.

In addition, the central layers of direct heterodimer contacts are flanked on each side by a cholesterol molecule. One mediates the interaction between TM5 helices of both subunits

(CLR3), while the other bridges TM3 of GABA_{B1b} and TM5 of GABA_{B2} (CLR6) (Extended Data Fig. 5g).

The 'intersubunit latch'

To determine the importance of the 'intersubunit latch' in controlling the inactive state of GABA_B receptor, we examined the effect of single charge-repelling mutations (GABA_{B1b}-E673R; GABA_{B2}-H579E) within the motif. Wild-type GABA_B receptor exhibited basal activity in the absence of agonist (Fig. 2b), as previously reported¹⁴. Both mutants substantially increased basal activity when compared to wild-type, suggesting that each mutation promotes agonist-independent constitutive activity (Fig. 2b). The basal activity displayed by these mutants reached approximately 80–90% of the maximal agonist-dependent wild-type response (Fig. 2b,c). Application of the agonist baclofen raised receptor activity further to the highest wild-type level (Fig. 2c). Neither mutation altered the agonist potency. After treating each construct with the inverse agonist CGP54626, the basal activity of mutants still remained higher than that of wild-type, providing further evidence that the 'intersubunit latch' mutations serve to shift the conformational equilibrium of GABA_B receptor towards an active state. Taken together, our mutational data indicate that the 'intersubunit latch' is fundamental to maintaining the inactive state of the receptor.

Endogenous ligands bound to GABA_{B1b} VFT

We identified a novel potential Ca²⁺-binding site in the vicinity of the orthosteric ligand-binding cleft on the LB2 surface of GABA_{B1b} (Fig. 3a; Extended Data Fig. 6a,b). The metal ion density has remarkable peak height in the cryo-EM density map (10 σ) and is surrounded by residues chemically favorable for Ca²⁺ coordination. The Ca²⁺ is anchored by the carboxylate groups of three acidic residues (Asp281, Glu309, and Glu423) as well as the backbone carbonyl atoms of two additional residues (Gly277 and Tyr279) (Fig. 3b). The Ca²⁺-oxygen bond distances are between 3.0 Å and 4.6 Å, suggesting that the ion is in a hydrated state. The Ca²⁺ location in GABA_{B1b} is different from any of the multiple sites found in calcium-sensing (CaS) receptor²¹, another class C GPCR (Fig. 3c).

Using inductively coupled plasma mass spectroscopy, we detected the presence of Ca and Cu above background level in purified GABA_B receptor. The amounts of other metal elements were negligible (Supplementary Table 3). The molar ratios of Ca and Cu relative to the receptor protein (0.43:1 and 0.51:1) suggest partial occupancy of the ion-binding sites. An unmodeled density within the interdomain cleft, coordinated by tryptophan and histidine, may serve as a potential Cu²⁺-binding site but lacks sufficient signal to be labeled confidently.

In exploring the functional role of the bound ion, we found that the Ca²⁺ chelator EGTA substantially reduced GABA_B receptor basal activity, and that mutating specific coordinating residues (GABA_{B1b}-E309K and GABA_{B1b}-E423R) had similar, although less drastic, effects (Extended Data Fig. 6c,d). Consistent with previous findings, these data suggest that Ca²⁺ may act as a positive allosteric modulator of GABA_B receptor^{22,23}. Our structure implies

that Ca^{2+} stabilizes residues adjacent to the critical agonist-binding residue Trp278, thereby indirectly reinforcing its conformation (Fig. 3b).

We also found density in the orthosteric agonist-binding site of $\text{GABA}_{\text{B}1\text{b}}$, and its shape suggests a GABA-like endogenous ligand (Extended Data Fig. 6a,b). GABA is a potential candidate since it fits the density and was detected in the lysate of cells used to express the receptor (Extended Data Fig. 6e,f). This GABA-like endogenous ligand bound in an inactive receptor conformation may reflect a pre-activation state; however, further investigation is required.

Discovery of endogenous phospholipid ligands

Our structure revealed endogenous phospholipids within the TM domains of both GABA_{B} subunits. Using CaS receptor as control in mass spectrometry, we identified two phospholipids specifically bound to GABA_{B} receptor, PE 38:5 and PC 38:2 (Fig. 4a–d). Both lipids consist of two long-chain fatty acyl moieties of 18 and 20 carbons. We further assigned PE 38:5 to $\text{GABA}_{\text{B}1\text{b}}$ and PC 38:2 to $\text{GABA}_{\text{B}2}$ based on the size difference between phosphoethanolamine and phosphocholine head groups of the two lipids (Extended Data Fig. 7a,b). The lipid density in the $\text{GABA}_{\text{B}2}$ TM domain has a bulkier head group that can better accommodate the larger choline moiety of PC 38:2.

Mirroring the amphipathicity of phospholipids, the lipid-binding pocket of each GABA_{B} subunit retains a hydrophilic trunk and two lipophilic branches for binding the lipid polar head and nonpolar tails, respectively. The trunk consists of a negatively charged patch covering the amine moiety, and a positively charged area surrounding the phosphate (Extended Fig. 7c,d). The lipid-binding pockets are notably deep, extending from the extracellular membrane surface to the center of the TM domain (Fig. 4e,f). Each lipid occupies nearly the entire range of ligand-binding positions in class A, B, C and F GPCRs (Extended Data Fig. 7e–h).

Each GABA_{B} subunit makes extensive contacts with the bound lipid, utilizing a majority of the TM helices, including TM2, 3, 5, 6, and 7 (Extended Data Fig. 7i,j). Approximately $2,400 \text{ \AA}^2$ of surface area is buried by either lipid-subunit pair. In addition, ECL2 directly contacts PE 38:5 in $\text{GABA}_{\text{B}1\text{b}}$, while the linker and all three ECLs interact with PC 38:2 in $\text{GABA}_{\text{B}2}$.

Key elements of the lipid-receptor interactions are conserved in $\text{GABA}_{\text{B}1\text{b}}$ and $\text{GABA}_{\text{B}2}$ (Fig. 4g–j; Extended Data Figs. 7i,j; Supplementary Fig. 3). First, the hydrophilic head of each lipid is anchored through interactions with conserved histidine and arginine residues ($\text{GABA}_{\text{B}1\text{b}}$: His643 of ECL2 and Arg549^{3,32}; $\text{GABA}_{\text{B}2}$: His647 of ECL2 and Arg556^{3,32}) (Fig. 4g,h). $\text{GABA}_{\text{B}2}$ also incorporates Arg714 of ECL3, rendering the lipid-binding pocket more electropositive than that of $\text{GABA}_{\text{B}1\text{b}}$ (Fig. 4h).

Second, the 20-carbon fatty acyl chain of both lipids follows a perpendicular turn to pass between two aromatic residues ($\text{GABA}_{\text{B}1\text{b}}$: Phe557^{3,40} and Tyr657^{5,44}; $\text{GABA}_{\text{B}2}$: Tyr564^{3,40} and Tyr661^{5,44}) (Fig. 4i,j). A cis double bond in each fatty acyl chain forms π interactions with the aromatic side chains. The bend is further buttressed by extensive

nonpolar contacts with the aliphatic part of a conserved lysine (GABA_{B1b}-Lys660^{5,47}; GABA_{B2}-Lys664^{5,47}) lying parallel to the chain. Finally, the 18-carbon fatty acyl chain of both lipids is relatively straight, extending toward the cytoplasm in a binding pocket lined by small aliphatic residues on TM2, 3, and 7 (Fig. 4i,j).

The GABA_B receptor TM domains are covered by the linker and ECLs, which form a lid over the lipid-binding pocket. Phospholipids may access the lipid-binding pocket of designated subunits laterally through gaps between TM5 and 6 (Extended Data Fig. 8a–d). One of the fatty acyl tails of each phospholipid even protrudes through this opening. The lipid-binding sphingosine 1-phosphate (S1P₁) receptor possess a similar gap between TM1 and TM7²⁴ (Extended Data Fig. 8e,f). The endogenous lipids of other GPCRs can be readily replaced²⁴, but the size and engagement of the endogenous lipids bound to GABA_B receptor suggest that they are critical for maintaining receptor integrity and stability.

To explore the physiological relevance of the endogenous phospholipids, we mutated residues that hydrogen bonded with the phosphate head group. We identified R714A in GABA_{B2} ECL3, which displayed a small gain of function despite reduced cell surface expression (Extended Data Fig. 8g,h). This mutation is expected to enhance the movement of PC 38:2 within GABA_{B2} by eliminating a critical interaction with the lid. Our results suggest that PC 38:2 may act as a negative allosteric modulator of GABA_B receptor by stabilizing the inactive conformation of GABA_{B2}.

Comparison of individual subunits with other GPCRs

The GABA_{B1b} and GABA_{B2} subunits have highly similar VFT and TM components but differ in their relative orientation (Extended Data Fig. 9a,b). Each subunit differs from all other class C GPCRs in possessing an extended peptide linker between the VFT and TM domain instead of a cysteine-rich domain. (Fig. 1c).

GABA_B subunits also display distinct helix positions in the seven-helix bundles among inactive GPCRs (Extended Data Fig. 9c–f). However, these differences are minor compared to the dramatic movement of TM6 in class A and B GPCRs when activated upon G protein coupling^{25,26}. This corroborates our conclusion that we have captured an inactive conformation of the GABA_B receptor.

GABA_B receptor presents unique variations of conserved TM motifs (Extended Data Fig. 10a,b). In most class A GPCRs such as rhodopsin²⁷, the 'ionic lock' tethers TM3 and TM6 to stabilize the inactive state of an individual TM domain²⁷ (Extended Data Fig. 10c). The 'ionic locks' of both GABA_B subunits consist of an aspartate from ICL3 and a lysine in TM3 (3.50) (Extended Data Fig. 10a,b). Although only the Lys/Asp pair in GABA_{B1b} are within hydrogen bond distance, their backbone Cα–Cα separations (9.3–9.4 Å) are comparable to that of rhodopsin²⁷ (8.7 Å) and inactive mGlu receptors^{28,29} (10.9–11.2 Å), indicating that the 'ionic lock' is intact within both GABA_B subunits (Extended Data Fig. 10a–e).

The 'ionic lock' in each GABA_B subunit resides in close proximity to an FxPKxx sequence in TM7, which is the counterpart of the NPxxY(x)_{5,6}F motif in class A GPCRs²⁵.

Specifically, the conserved Lys^{7.51} participates in a network of hydrophilic contacts with the 'ionic lock' through Asn^{2.39} and a serine in ICL1 (Extended Data Fig. 10a, b; Supplementary Fig. 3). These interactions unite the 'ionic lock' and FxPKxx motif into a larger and integral system for maintaining the inactive TM conformation of individual GABA_B subunits.

Conclusion

The combination of our previous VFT structures and current cryo-EM data supports the occurrence of three critical events during GABA_B receptor activation: (1) agonist-induced VFT closure of GABA_{B1b}, (2) association of membrane-proximal LB2 domains, and (3) dissociation of the 'intersubunit latch' and the ensuing rearrangement of the TM heterodimer interface. This hypothesis is consistent with our finding that an inverse agonist bound to the extracellular domain can inhibit the constitutive activity stemming from the spontaneous closure of GABA_{B1b} VFT, but not that resulting from direct 'downstream' disruption of the 'intersubunit latch'.

The GABA_B receptor structure also yields surprising findings regarding its endogenous ligand composition. We suspect that the phospholipids discovered well inside each TM cavity are necessary structural components, as they are pre-bound within each subunit and their interactions with the receptor are extensive. These endogenous lipids may be unique to GABA_B receptor since the lipid-binding residues are not conserved among class C GPCRs (Supplementary Fig. 3). Pre-occupation of the TM pocket suggests that GABA_B allosteric modulators may bind to yet unknown sites, with the heterodimer interface being a potential location. An active structure of GABA_B receptor would confirm whether the phospholipids are integral receptor components or functional modifiers.

Methods

Protein expression and purification

Human GABA_{B1b} (UniProt code: Q9UBS5-2) and GABA_{B2} (UniProt code: O75899) subunits were each cloned into a modified pEG BacMam vector³⁰ for co-expression in baculovirus-infected mammalian cells. GABA_{B1a} and GABA_{B1b} are two major isoforms of GABA_{B1}, and have identical pharmacological profiles⁷. Different C-terminal truncations of each receptor subunit were tested for heterodimeric receptor assembly. The optimal GABA_{B1b} expression construct consisted of residues 1–802 [GABA_{B1b}(1–802)], while GABA_{B2} construct included residues 1–819 [GABA_{B2}(1–819)]. This allowed the heterodimeric construct to transport to the cell membrane as it retained the intracellular coiled-coil region present in the intracellular tails of each subunit^{31,32}. Signal peptides for GABA_{B1b} and GABA_{B2} occupied residues 1–29 and 1–41, respectively. A Flag tag was engineered at the C terminus of each subunit to facilitate affinity purification.

Human embryonic kidney (HEK) 293 GnTI[−] cells³³ were grown in suspension culture at 37°C in 8% CO₂ using 293 freestyle media (Life Technology, Carlsbad, USA). The cells were co-infected with recombinant baculoviruses carrying the GABA_{B1b}(1–802) and GABA_{B2}(1–819) genes at 37°C. To enhance expression level, 10 mM sodium butyrate was

added 18 hours post infection, and the cells were incubated for an additional 72 hours at 30°C before harvest.

Cell membrane was isolated by differential centrifugation method. The cells were lysed using an EmulsiFlex-C3 high pressure homogenizer (Avestin, Ottawa, Canada) in a buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol and a cocktail of protease inhibitors (Roche, Basel, Switzerland). Cell debris was removed by centrifugation of the lysed cell suspension at 10,000 rpm. The cell membrane was then pelleted by ultracentrifugation at 45,000 rpm.

GABA_B receptor was extracted from the cell membrane with 50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% lauryl maltose neopentyl glycol (LMNG) (Anatrace, Maumee, USA), and 0.2% cholesteryl hemisuccinate (CHS) (MilliporeSigma, Burlington, USA) at 4°C overnight. After the insoluble matter was removed by centrifugation, the supernatant was applied to an anti-Flag M2 antibody affinity column. The column was washed stepwise with decreasing concentrations of detergent, from 0.1% to 0.002% LMNG. The heterodimeric GABA_{B1b}(1–802)-GABA_{B2}(1–819) complex was then eluted with 50 mM HEPES, pH 7.5, 50 mM NaCl, 0.002% LMNG, 0.0004% CHS, and 0.2 mg/ml Flag peptide.

The receptor was further purified by Mono Q (GE Healthcare, Chicago, USA) ion exchange chromatography using a linear salt gradient from 50 mM to 1 M NaCl in 50 mM HEPES, pH 7.5, 0.002% LMNG, and 0.0004% CHS. Finally, the assembled GABA_B receptor was subjected to Superose 6 (GE Healthcare, Chicago, USA) size exclusion chromatography in 50 mM HEPES, pH 7.5, 50 mM NaCl, 0.002% LMNG, and 0.0004% CHS.

HEK 293 GnT1[−] cells were purchased from and authenticated by American Type Culture Collection (ATCC No. CRL-3022). Cell morphology was examined for each passage of cells. The cells were certified by ATCC to be free of mycoplasma contamination, but they were not tested again during culturing.

Cryo-EM specimen preparation and data acquisition

Specimens were composed of vitrified GABA_B protein samples occupying UltraAuFoil R 0.6/1, 300 mesh holey Au/Au grids (Quantifoil Micro Tools, Jena, DEU). The surfaces of the grids were rendered hydrophilic by glow-discharging using H₂ and O₂ for 25 seconds at 10 watts with a Solarus 950 plasma cleaner system (Gatan, Cranberry, USA). For vitrification, 3ul of purified GABA_B receptor at a concentration of approximately 0.3 mg/ml was applied to each grid, blotted for 4 seconds at a blot force of 3 inside a Vitrobot Mark IV (Thermo Fisher Scientific, Waltham, USA), and plunge-frozen in a liquid propane:ethane mixture (63:37, v/v) cooled with liquid nitrogen.

Data collection was performed on a Titan Krios transmission electron microscope (Thermo Fisher Scientific, Waltham, USA) equipped with a K2 Summit direct electron detection camera (Gatan, Cranberry, USA) in counting mode and a post-column GIF Quantum energy filter (Gatan, Cranberry, USA) in zero-energy-loss mode with a slit width of 20 eV. Micrographs were accrued at a calibrated pixel size of 1.06 Å and with nominal defocus range of −0.5 to −2 μm. Each micrograph consisted of 60 frames collected over a 12-second

exposure at a dose rate of $\sim 8 \text{ e}^-/\text{pixel}/\text{second}$ for a total dose of $\sim 85 \text{ e}^-/\text{\AA}^2$. A total of 3,435 micrographs were acquired as dose-fractionated image stacks.

Cryo-EM image processing

Image processing began with frame alignment and dose-weighting of the image stacks using the CPU-based implementation of MotionCor2³⁴ in Relion 3.0³⁵. Estimation of contrast transfer function (CTF) for each non-dose weighted micrograph was determined by Gctf³⁶ v1.06. After visual inspection of the micrographs and their power spectra, 3,334 were selected for further processing.

Approximately 3,000 particles were manually picked in Relion 3.0³⁵, and extracted from a 4x binned dataset with a pixel size of 4.24 $\text{\AA}$. This data produced an initial set of two-dimensional (2D) classes that were used as templates to select 1,048,241 particles automatically, all of which were subsequently imported into cryoSPARC v2³⁷ for extensive 2D classification. After elimination of unfit classes, a total of 312,840 particles from the high-quality 2D classes were combined to produce an *ab initio* 3D reference in cryoSPARC v2³⁷. Based on the *ab initio* model, particles were re-extracted at full scale from the unbinned dataset with a pixel size of 1.06 $\text{\AA}$ in Relion 3.0³⁵, and re-introduced into cryoSPARC v2³⁷ for 3D refinement. Homogeneous refinement of the *ab initio* 3D model against the unbinned set of particles yielded a density map with nominal resolution of 3.6 $\text{\AA}$ according to the Fourier shell correlation (FSC) = 0.143 gold standard criterion³⁸. Heterogeneous refinement of multiple models obtained before and after homogeneous refinement allowed removal of additional poor-quality particles and reduced the particle count to 233,737. Non-uniform refinement then improved the resolution to 3.5 $\text{\AA}$. At this point, CTF refinement and Bayesian polishing were conducted in Relion 3.0³⁵, followed by an additional round of non-uniform refinement in cryoSPARC v2³⁷, further improving the resolution to 3.3 $\text{\AA}$.

Although the TM domains of GABA_B receptor exhibit pseudo two-fold symmetry, bulky carbohydrate densities that are visible only in the ECD of GABA_{B1b} subunit resulted in sufficient low-resolution asymmetry to prevent particle misalignment. These include partial carbohydrate densities attached to Asn323 and Asn365 of GABA_{B1b} that do not have counterparts in GABA_{B2}.

The global density map exhibited directional anisotropy³⁹ that is caused by inter-domain movement about a flexible linker. To eliminate the adverse effect of such movement on map quality, we performed local refinement of the ECD and TM domains of GABA_B receptor independently. A mask was created covering each region, and the non-uniform refinement algorithm was used as implemented in cryoSPARC v2³⁷. The resulting reconstructions for the individual ECD and TM domains reached 3.1 $\text{\AA}$ and 3.4 $\text{\AA}$ resolution, respectively. A composite map was generated in UCSF Chimera⁴⁰ by taking the maximum values pointwise from the two locally refined maps after alignment to the global reconstruction (*vop maximum* command in UCSF Chimera⁴⁰). This composite map was used for subsequent model building and refinement.

Resolutions of cryo-EM reconstructions were determined using a cutoff value of 0.143 in gold standard half-map Fourier shell correlation (FSC) curves³⁸.

Three-dimensional (3D) variability analysis⁴¹ was conducted in cryoSPARC v2³⁷ using the 233,737 particles from global non-uniform refinement as input. Calculations were performed for the entire receptor, the ECDs, and the TM domains, respectively. In each case, multiple modes of variability were solved, and represented as eigenvectors along which conformational changes occur. To visualize the transformation of density, five reconstructions were calculated along each eigenvector, with a filter resolution of 4.5 Å. A movie that combines these reconstructions as frames was generated in Chimera⁴⁰ for each dimension of motion.

Model building and refinement

Model building was carried out in COOT⁴². The crystal structure of human GABA_{B1b} VFT-GABA_{B2} VFT complex in the apo form (PDB code: 4MQE) was used as the initial model for extracellular domain of the receptor. The VFT modules of GABA_{B1b} and GABA_{B2} were separately placed into density as rigid bodies. Individual residues were then adjusted to optimize the fit. The linker and TM domain of each subunit was traced *de novo* based on the density. The final model contained residues 48–368, 377–576 and 588–747 of GABA_{B1b}, and 54–294, 302–376, 385–584, and 595–749 of GABA_{B2}.

In addition to the polypeptide chains, we built models for a Ca²⁺ in the extracellular domain of GABA_{B1b}, as well as one phospholipid (PE 38:5 in GABA_{B1b}; PC 38:2 in GABA_{B2}) within the TM domain of each subunit. Density for carbohydrate was observed at three N-linked glycosylation sites on GABA_{B1b} (Asn365, Asn385 and Asn397), and one site on GABA_{B2} (Asn404). An N-glucosamine residue was modeled at each of these glycosylation sites. Continuous density was also identified for ten cholesterol or CHS molecules surrounding the TM domains of both GABA_B subunits. Cholesterols were modelled to optimize the fit with density, however, these densities may belong to CHS molecules with disordered parts. Density for an endogenous ligand was found at the interdomain cleft of GABA_{B1b} VFT. Although this density could be fit with GABA, it was not modelled because the origin and identity of the ligand remained ambiguous without confirmation by an independent method.

The entire structure was refined by the real-space refinement algorithm, and validated with the comprehensive validation application as implemented in Phenix⁴³. Ramachandran statistics was calculated using MolProbity⁴⁴. The refined model also has an overall EMRinger⁴⁵ score of 2.7, while the extracellular and TM domains have scores of 3.4 and 1.8, respectively. The final model revealed that VFT and TM components are related to their counterparts in the other subunit by 177° and 179°-rotations about the vertical axis, respectively.

Pairwise structural alignment was performed using LSQMAN⁴⁶. Figures were generated using Pymol Molecular Graphics System Version 2.3 (Schrödinger), UCSF Chimera⁴⁰ and UCSF ChimeraX⁴⁷. Software installation support was provided by SBGrid⁴⁸.

Scintillation proximity assay

Binding of [^3H]GABA (60 Ci/mmol; American Radiolabeled Chemicals, Inc., St. Louis, USA) to GABA_B receptor was measured with the scintillation proximity assay (SPA)^{49,50}. Purified GABA_{B1b}(1–802)-GABA_{B2}(1–819) complex (100 ng) was extensively dialyzed against the purification buffer to remove any residual endogenous ligand. The dialyzed protein was then immobilized to yttrium silicate (YSi) protein A SPA beads (62.5 μg) (PerkinElmer, Waltham, USA) using anti-Flag M2 antibody (12.5 μg) (Sigma-Aldrich, Inc., St. Louis, USA), and incubated at 4°C for 30 minutes in the same buffer as used for the final step of protein purification (50 mM Hepes, pH 7.5, 50 mM NaCl, 0.002% LMNG, 0.004% CHS). Increasing concentrations (ranging from 0.2–25 μM) of [^3H]GABA (2.5 Ci/mmol final specific radioactivity) were added to the protein/antibody/SPA-bead mixture and the samples were allowed to reach equilibrium at 4°C for 16 hours. Reaction performed with an antibody/SPA-bead mixture in the absence of GABA_B receptor was used to determine the non-proximity signal originating from non-specific interaction between the radioligand and SPA beads.

All samples were counted in a MicrobetaTM counter (PerkinElmer, Waltham, USA) in counts per minute (cpm) in the SPA mode. The efficiency of detection was calculated with a standard curve of known [^3H]GABA concentrations, and this was used to transform cpm into pmol. Specific binding was determined by subtracting the non-proximity signal (non-specific binding) from the total binding signal and was plotted as a function of free radioligand concentration. Nonlinear regression fitting of the data was performed in SigmaPlot 13.0 to obtain the dissociation constant (K_d) and the molar ratio of GABA-to-receptor binding.

Identification of phospholipid ligands and GABA

Identification of bound endogenous lipids was conducted utilizing published protocol⁵¹ with modifications. Briefly, intact GABA_B and control CaS receptor were digested with trypsin overnight at 37°C. Digested proteins were dried and extracted with 1 mL of ice-cold methanol:water (9:1, v/v). The supernatants were dried and re-suspended with methanol:toluene (9:1, v/v) to equivalent concentration of 2 μM . For LC-MS/MS analysis⁵², the lipid extracts were separated on a Waters Acquity UPLC CSH C18 column (100 $\times$ 2.1 mm; 1.7 μm) coupled to an Acquity UPLC CSH C18 VanGuard precolumn (5 $\times$ 2.1 mm; 1.7 μm). The column was maintained at 65°C at a flow rate of 0.6 mL/min. The mobile phases consisted of A: acetonitrile:water (60:40, v/v) with ammonium formate (10 mM) and formic acid (0.1%), as well as B: 2-propanol:acetonitrile (90:10, v/v) with ammonium formate (10 mM) and formic acid (0.1%). The 15 min separation was conducted under the following gradient: 0 min 15% B; 0–2 min 30% B; 2–2.5 min 48% B; 2.5–11 min 82% B; 11–12 min 99% B; 12–15 min 15% B. Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Waltham, USA) was operated in electrospray ionization (ESI) in positive mode with the following parameters: mass range 100–1500 m/z; spray voltage +3.6 kV; sheath gas (nitrogen) flow rate 60 units; auxiliary gas (nitrogen) flow rate 25 units, capillary temperature 320°C, full scan MS1 mass resolving power 60,000, data-dependent MS/MS acquisition (dd-MS/MS) 4 scans per cycle, dd-MS/MS mass resolving power 15,000. The mass features that were differentially higher in GABA_B receptor were subjected to targeted

MS/MS in re-injections to acquire tandem mass spectra. Thermo Xcalibur 4.0.27.19 was used for data acquisition. Data processing and identification were performed in MS-DIAL v3.40. Identification was conducted by matching accurate mass, tandem mass spectra, and chromatographic retention time with built-in lipid library LipidBlast⁵³. The identified endogenous lipids bound to GABA_B receptor include phosphatidylcholine (PC) 38:2 [PC(18:1_20:1); International Chemical Identifier (InChI) Key: [QLEJPADMSQQACL-WWUFLCHTSA-N](#)], and phosphatidylethanolamine (PE) 38:5 [PE(18:1_20:4); InChIKey: [VFUVYNGTMNUBMF-ZRVIQYDLSA-N](#)]. Although many isoforms exist for these lipids, both phospholipids share two long-chain fatty acyl moieties of 18 and 20 carbons based on mass spectrometry fragmentation pattern and biological relevance.

Identification of GABA was conducted in targeted LC-MS/MS. Briefly, cell supernatant, cell lysate, together with culture media and lysis buffer controls were dried from 1 mL and extracted with 1 mL of ice-cold methanol:water (9:1, v/v). The supernatants were dried and re-suspended with 200 μ L of acetonitrile:water (8:2, v/v). The extracts were separated on a Waters Acquity UPLC BEH Amide column (150 $\times$ 2.1 mm; 1.7 μ m) coupled with an Acquity UPLC BEH Amide VanGuard precolumn (5 $\times$ 2.1 mm; 1.7 μ m). The column was maintained at 45 °C at a flow rate of 0.4 mL/min. Mobile phase A was water with ammonium formate (10 mM) and formic acid (0.125%) while B was acetonitrile:water (95:5, v/v) with ammonium formate (10 mM) and formic acid (0.125%). Separation was conducted using the gradient: 0–2 min 100% B; 2–7.7 min 70% B; 7.7–9.5 min 40% B; 9.5–12.5 min 30% B; 10.25–12.75 100% B, 12.75–16.75 100% B. Q Exactive HF mass spectrometer was operated in the same parameters as above. GABA standard was injected along with the samples to confirm its spectrum and retention time. The responses of GABA in samples were normalized to that of GABA standard with known concentration.

Cell surface expression

Full-length human GABA_{B1b} and GABA_{B2} were each cloned into a pcDNA3.1(+) vector (Life Technologies, Carlsbad, USA), with a Flag tag inserted after the signal peptide of GABA_{B1b}, and an HA tag after the signal peptide of GABA_{B2}. Similar constructs were also generated for the C-terminally truncated GABA_{B1b}(1–802) and GABA_{B2}(1–819). Single mutants of full-length GABA_{B1b} (E673R, E309K, and E423R) and GABA_{B2} (H579E, R714A) were constructed using the QuikChange mutagenesis system (Agilent Technologies, Santa Clara, USA).

The cell surface expression levels of wild-type (WT) and mutant GABA_B receptor were measured following previously published protocol¹⁷. Briefly, HEK293 T/17 cells (ATCC) were cultured in monolayer in DMEM/F12 media (Life Technology, Carlsbad, USA) supplemented with 10% FBS at 37°C in the presence of 5% CO₂. The cells were co-transfected with GABA_{B1b} and GABA_{B2} plasmids using Lipofectamine 3000 (Life Technologies, Carlsbad, USA). Each GABA_{B1b} and GABA_{B2} mutant was paired with its wild-type partner. Since GABA_{B1b} is retained inside the cells unless it is chaperoned by GABA_{B2}, we used the surface expression level of GABA_{B1b} on intact cells to measure the amount of assembled heterodimeric GABA_B receptor on the cell surface. The amount of surface GABA_{B1b} protein detected for each pair of constructs was normalized with the cell

count in each experiment. The cell surface expression level of each mutant is calculated as a percentage of the wild-type receptor.

After blocking with 1% BSA, the cells were incubated with mouse anti-Flag M1 antibody (MilliporeSigma, Burlington, USA) as the primary antibody to measure GABA_{B1b} expression, followed by donkey anti-mouse IRDye 800-labeled antibody (Li-Cor Biosciences, Lincoln, USA) as the secondary antibody. Fluorescent signals were measured with an Odyssey Infrared Imager (Li-Cor Biosciences, Lincoln, USA). Each experiment was performed in triplicates.

HEK 293 T/17 cells were purchased from and authenticated by American Type Culture Collection (ATCC No. CRL-11268). Cell morphology was examined for each passage of cells. The cells were certified by ATCC to be free of mycoplasma contamination, but they were not tested again during culturing.

Inositol phosphate measurement

HEK293 T/17 cells were co-transfected with plasmids encoding GABA_{B1b}, GABA_{B2}, and Gα_{qi5}. The Gα_{qi5} chimera was constructed by replacing the five C-terminal amino acids of murine Gα_q with those of murine Gα_i¹⁸. Exchanging the C-terminal end of Gα_q with that of G_{i/o} permits it to couple with GABA_B receptor and allows the functional activity of the receptor to be tracked through phospholipase C (PLC). Control experiments were conducted using cells transfected with an empty pcDNA3.1(+) vector, Gα_{qi5} alone, or wild-type GABA_{B1b} and GABA_{B2} in the absence of Gα_{qi5}.

Inositol phosphate (IP) accumulation was quantified with the homogenous time-resolved fluorescence (HTRF) IP-one Tb kit (Cisbio Bioassays, Codolet, FRA), which measures the accumulation of inositol 1-monophosphate (IP₁), a metabolite of inositol 1,4,5-triphosphate (IP₃). One day post transfection, the cells were stimulated with increasing concentrations of baclofen for one hour at 37°C. The stimulated cells were lysed, and the native IP₁ which had been produced was incubated with a d2 fluorophore-labeled IP₁ analog (acceptor) to compete for binding to an Eu Cryptate-coupled anti-IP1 monoclonal antibody (donor). The fluorescence data was collected at 620 and 665 nm with a PHERAstar FS plate reader (BMG LABTECH, Cary, USA) after laser excitation at 320 nm. The fluorescence resonance energy transfer (FRET) signal was calculated as the fluorescence ratio (665 nm/620 nm) and is inversely proportional to the concentration of native IP₁ produced following GABA_B activation through a chimeric Gα_{qi5} G protein. The agonist-induced receptor response of each mutant was calculated as a percentage of the maximum activity of wild-type receptor relative to the activity observed for Gα_{qi5} alone. Basal activity was determined in the absence of baclofen stimulation and calculated similarly as the agonist-dependent receptor response. Data analysis was performed using the non-linear regression algorithms in Prism (GraphPad Software, San Diego, USA). Data points represent average ± s.e.m. of multiple experiments, each consisting of quadruplicate measurements.

Application of a known antagonist, CGP54626, reduced agonist potency as expected. In addition, the compound lowered the basal activity of GABA_B receptor, indicating that it has

inverse agonist activity as previously reported⁵⁴. Therefore, we refer to the compound as an inverse agonist.

Inductively coupled plasma mass spectrometry

Purified GABA_B receptor (200 µl, 11.1 µg/µl or 57.7 µM) was collected in metal-free tubes and digested overnight with the addition of 1 mL of concentrated nitric acid (HNO₃) (Fisher, Hampton, USA; Optima grade). The digested protein was then diluted to a total volume of 10 ml with 8.7 ml of deionized water supplemented with 500 µg/L of gold (Au) and 100 µL of an internal standard solution containing 500 µg/L each of gallium (Ga) and rhodium (Rh) in 2% HNO₃. The protein purification buffer (200 µl) containing 10 mM HEPES, pH 7.5, 50 mM NaCl, 0.002% LMNG, and 0.0004% CHS, was similarly mock digested and diluted for analysis.

Inductively coupled plasma mass spectrometry (ICP-MS) was conducted using a NexION 350S ICP-MS instrument (Perkin Elmer, Waltham, USA) equipped with dynamic reaction cell (DRC) feature and a SC-4 DX FAST Autosampler (Elemental Scientific, Omaha, USA). The DRC-ICP-MS experimental method was developed based on previously published procedures^{55,56} and a laboratory protocol for multi-element DCR-ICP-MS from the Centers for Disease Control (CDC) (https://www.cdc.gov/nchs/data/nhanes/nhanes_13_14/UM_UMS_UTAS_UTASS_H_MET.pdf). The concentrations of magnesium (Mg), calcium (Ca), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn) and strontium (Sr) in the digested protein and buffer samples were measured. Data points represent average ± c.v. of eight measurements within two experiments, where c.v. corresponds to coefficient of variance.

One multi-element calibration standard was prepared from concentrated single-element stocks, and used for instrument calibration. The calibration standard was diluted to various concentrations using a solution containing 10% HNO₃ and 500 µg/L of Au to cover the expected concentration range of each analyte in the protein sample: 0.01, 0.02, 0.05, 0.1, 0.2 µg/L for Co and Sr; 0.05, 0.1, 0.25, 0.5, 1.0 µg/L for Mn and Ni; 0.25, 0.5, 1.25, 2.5, 5.0 µg/L for Mg and Cu; 0.5, 1.0, 2.5, 5.0, 10.0 µg/L for Fe and Zn; and 2.5, 5.0, 12.5, 25, 50 µg/L for Ca.

The instrument was also calibrated against a set of blank solutions, including commercially available quality controls containing digested hair samples from Public Health Expertise and Reference Center, Quebec (INSPQ, Quebec, Canada), and a water sample containing a broad range of metals from National Institute of Technology (NIST, Gaithersburg, USA).

Special attention was given to correction for matrix-induced interferences. Matrix suppression was compensated by the selection of suitable internal standards, which were matched to masses and, if possible, to ionization properties of the analytes. The internal standards were added to each calibration standard and quality control sample to the same final concentrations as that in the protein sample and buffer (5 µg/L each of Ga and Rh). The elements Mg, Ca, Mn, Fe, Co, Ni, Cu, and Zn were corrected with Ga, while Sr was corrected with Rh. Polyatomic interferences were suppressed with the instrument's DRC

technology feature, utilizing ammonia as a second gas for Mn and Fe, while Mg, Ca, Sr, Co, Ni, Cu, and Zn were measured in standard mode without a second gas.

MALDI mass spectrometry

Purified GABA_{B1b}-GABA_{B2} complex (0.3 mg/ml, 1 μ l) was mixed with 1 μ l sinapinic acid matrix solution (Bruker Daltonics, Billerica, USA) containing 10 mg of sinapinic acid in 1 ml of 2.5% trifluoroacetic acid (MilliporeSigma, Burlington, USA) and 50% acetonitrile (MilliporeSigma, Burlington, USA). The protein-matrix suspension (2 μ l) was added to the ground steel MALDI target plate and dried at room temperature. Mass spectra were collected using a UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonic, Billerica, USA) operated with FlexControl software in linear positive mode, i.e. using a mass range of 30,000 to 120,000 daltons. The instrument was externally calibrated with Proteins MALDI-MS calibration kit (MilliporeSigma, Burlington, USA). Each individual mass spectrum was analyzed and adjusted for smoothness and baseline using FlexAnalysis software 3.0 (Bruker Daltonics, Billerica, USA). The molecular mass of the heterodimeric GABA_{B1b}-GABA_{B2} complex was determined to be 192,647.967 daltons.

Extended Data

Extended Data Fig. 1 | Purification and functional analysis of human GABA_B receptor.

a, Superose 6 size exclusion chromatography profile of detergent-purified GABA_{B1b}(1–802)-GABA_{B2}(1–819) complex.

b, SDS PAGE gel of size exclusion peak fraction from (a) under reducing conditions. For gel source data, see Supplementary Fig. 2.

c, Dose-dependent [³H]GABA binding to purified GABA_{B1b}(1–802)-GABA_{B2}(1–819) complex, reaching maximum molar ratios of GABA-to-receptor binding at 0.98 ± 0.03 mol/mol. Data points represent the mean of triplicate measurements of a typical experiment. The

experiment was repeated four times with similar results. Data were subjected to non-linear regression fitting, and the kinetic constants are reported as mean $\pm$ s.e.m. of the fit.

d, Functional analysis comparison of full-length and truncated WT GABA_B receptor. Dose-dependent baclofen-stimulated receptor response in cells transiently expressing G α_{q15} (abbreviated as Gqi) with full-length GABA_B heterodimer or the C-terminally truncated GABA_{B1b}(1–802)-GABA_{B2}(1–819) complex. Cells transfected with G α_{q15} alone were used as negative control. Relative agonist-stimulated activity was measured by IP₁ accumulation and expressed as percentage of maximum wild-type activity induced by baclofen relative to the activity of G α_{q15} alone. Data points represent average $\pm$ s.e.m. of multiple experiments (n), each with quadruplicate measurements. Cell surface expression level was 106% for the GABA_{B1b}(1–802)-GABA_{B2}(1–819) complex in comparison with the full-length WT/WT heterodimer.

Extended Data Fig. 2 | Cryo-EM imaging of human GABA_B receptor.

- a**, Workflow of cryo-EM data processing.
- b**, A representative motion-corrected cryo-electron micrograph of GABA_B receptor.
- c**, Reference-free 2D class averages highlighting clear density for TM helices.
- d**, Global density map colored according to local resolution in full and clipped views perpendicular to the plane of the membrane.
- e**, Global FSC curve (purple) corrected by high-resolution noise substitution. The overall resolution as determined by an FSC cut-off value of 0.143 (blue line) is 3.3 Å.
- f**, 3D-FSC curves measuring directional resolution anisotropy. Plots show global half-map FSC (red solid line), together with the spread of directional resolution values within ± 1 standard deviation of the mean (area encompassed by green dash lines), and a histogram of 100 such directional resolution values sampled evenly over the 3D-FSC threshold value of 0.143 (blue, right axis). The sphericity value reported by 3D-FSC is 0.958 out of 1.
- g,h**, Separate FSC curves for the locally refined reconstructions of ECD (**g**) and TM (**h**) domains. Blue line marks the resolution corresponding to an FSC value of 0.143 (ECD: 3.1 Å; TM: 3.4 Å). The inset shows the mask used for each local refinement.

Extended Data Fig. 3 | Structural model of GABA_B receptor fit within the cryo-EM map. **a-d**, Cryo-EM density map and refined model are shown for the LB1 interface helices (H-B and H-C) in the extracellular VFT (**a**), the linker between VFT and TM domain (**b**), all seven TM helices of GABA_{B1b} subunit (**c**) the ten modeled transmembrane cholesterol (**d**) and all seven TM helices of GABA_{B2} subunit (**e**). The density map is a composite of the locally refined reconstructions for the ECD and TM domains. The N- and C-terminal residues of each helix are labeled.

Extended Data Fig. 4 |. Architecture of GABA_B receptor.

a, GABA_B receptor structure in four views related by 90°-rotations about an axis perpendicular to the membrane. GABA_{B1b} (blue) and GABA_{B2} (green) subunits are rendered as cartoon, while Ca²⁺ (green) is shown as a sphere. Phospholipids (PE 38:5 and PC 38:2; yellow) are presented as space-filling models. The observed N-linked glycans (NAG, gray) and cholesterol (CLR, pink) are in ball-and-stick models. TM helices 1 through 7, along with N- and C-termini, are marked for each subunit.

b, Cryo-EM density map of GABA_B receptor, in the same orientation and color scheme as (a). The map is composed of local reconstructions for the ECD and TM domains, which were independently refined to 3.1 Å and 3.4 Å, respectively.

c, Linker and TM domain of GABA_B receptor viewed from the extracellular and intracellular sides.

Extended Data Fig. 5 | Heterodimer conformation and interface features of the GABA_B receptor.

a,b, Cryo-EM structure of near full-length GABA_B receptor (cyan) superimposed with crystal structure of its extracellular VFT module in the inactive-state (PDB code: 4MQE; purple) (**a**) or active state (PDB code: 4MS3; red) (**b**). The middle panel shows the heterodimeric receptor structures superimposed based on the LB1 domain of GABA_{B1b} subunit. The two side panels show superposition of individual GABA_{B1b} and GABA_{B2} subunits based on their respective LB1 domains. In (**b**), Green line denotes the axis of rotation that relates the LB2 domains of near full-length and VFT structures of GABA_{B1b} (rotation $\chi = 28^\circ$, screw translation $\tau_\chi = 0.6 \text{ \AA}$), or near full-length and VFT structures of GABA_{B2} (rotation $\chi = 7^\circ$, screw translation $\tau_\chi = 0.3 \text{ \AA}$).

c,d, Extracellular LB2 domains viewed from the C-terminal end. Superposition of near full-length (cyan) and extracellular VFT structures (inactive state: purple (**c**); active state; red (**d**)) was based on the LB1 domain of GABA_{B1b} subunit. Within each heterodimeric

complex, the C-termini of the LB2 domains in GABA_{B1b} and GABA_{B2} subunits are shown as spheres, and the distance between the two C-termini is marked by a dotted line.

e, Cryo-EM structure of full-length mGlu₅ in the inactive (PDB code: 6N52) and active (PDB code: 6N51) conformations²⁰.

f, Molecular surface of GABA_{B1b}-GABA_{B2} complex showing the plane of heterodimer interface for extracellular and TM domains. Structural elements involved in heterodimer formation are highlighted in cartoon (ectodomain: H-B and H-C helices; TM domain: TM5 and TM3 helices).

g, GABA_B TM domain viewed from the extracellular side comparing the locations of core (I, II, IIIa, IIIb) vs. peripheral cholesterol-mediated heterodimer contacts from different layers. Heterodimer contacts mediated by two cholesterol (CLR6, CLR3) are displayed in panels at the bottom.

Extended Data Fig. 6 | Extracellular ligand binding in GABA_{B1b}.

a,b, Molecular surface (**a**) and ribbon representation (**b**) of GABA_{B1b} subunit showing the location of Ca²⁺-binding site and an unmodeled density at the interdomain crevice of VFT.

c,d, Functional analysis of the impact of endogenous Ca²⁺. Basal activity (**c**) and dose-dependent baclofen-stimulated receptor response (**d**) in cells transiently expressing the Gα_{qi5} (abbreviated as Gqi) with different combinations of WT and mutant GABA_B receptor subunits (GABA_{B1b}-E309K, abbreviated as E309K; GABA_{B1b}-E423R, abbreviated as E423R). IP₁ accumulation of WT/WT heterodimer was measured in the presence and absence of 2.5 mM EGTA. Cells transfected with Gα_{qi5} alone were used as negative control. Relative activity in both graphs is expressed as percentage of maximum wild-type activity induced by baclofen relative to the activity of Gα_{qi5} alone. Data points represent average ± s.e.m. of multiple experiments (n), each with quadruplicate measurements. ***P*=0.0016, ****P*=0.0002, *****P*<0.0001, one-way ANOVA with Bonferroni's post hoc test was used to calculate statistical differences in basal activity (**c**). Cell surface expression level was 107% for the E309K/WT and 87% for E423R/WT mutants in comparison with the WT/WT heterodimer.

- e, Fitting of GABA into the extra density (contoured at 7.0σ) at the orthosteric ligand-binding site and its potential interaction with GABA_{B1b}.
- f, Concentration of endogenous GABA in the supernatant and lysate of HEK 293 GnT⁻ cells after recombinant expression of GABA_B receptor, as well as cell culture media and lysis buffer controls, as detected by mass spectrometry.

Extended Data Fig. 7 |. Endogenous phospholipid-binding sites of GABA_B receptor.

- a,b, Ribbon representation of GABA_{B1b} (a) and GABA_{B2} (b) TM domain highlighting the cryo-EM density for phospholipids contoured at 4.0σ . Phospholipids are rendered in ball-and-stick representation.
- c,d, Electrostatic potential surface of the lipid-binding pocket in GABA_{B1b} (c) and GABA_{B2} (d). The phospholipids are shown in sphere models. Charged residues that directly contact the phosphate group of each lipid are marked.

e-h, Comparison of phospholipids bound to GABA_B subunits with ligands bound to class A GPCRs rhodopsin²⁷ (PDB code: 1F88) and S1P₁ receptor²⁴ (PDB code: 3V2Y) (**e**), class B GPCR corticotropin-releasing factor receptor 1⁵⁷ (CRF₁; PDB code: 4K5Y) (**f**), class C GPCRs mGlu₁²⁹ (PDB code: 4OR2) and mGlu₅²⁸ (PDB code: 4OO9) (**g**), and class F GPCR smoothened⁵⁸ (PDB code: 4JKV) (**h**). In each panel, the Cα trace of GABA_{B1b} linker and TM domain is shown in two orthogonal views in gray, and the superimposed GABA_B ligands PE 38:5 and PC 38:2 are in stick models in blue and green, respectively. Various GPCRs were overlapped onto the TM domain of GABA_{B1b} to bring their bound ligands into superposition

i,j, Schematic diagram of the specific contacts between GABA_{B1b} and PE 38:5 (**i**), and between GABA_{B2} and PC 38:2 (**j**). Selected contacts between residues and phospholipids are highlighted; hydrogen bonds, red dotted lines; hydrophobic contacts, black wiggled lines; polar interactions, green curved lines; pi-stacking interactions, orange box wave. Red zigzags indicate contacting atoms belong to main chain.

Lipid-interacting residues that are conserved in the two subunits are highlighted in bold and include: (1) head group (GABA_{B1b}: His643 and Arg549^{3,32}; GABA_{B2}: His647 and Arg556^{3,32}), (2) 20-carbon fatty acyl chain (GABA_{B1b}: Phe557^{3,40}, Tyr657^{5,44}, and Ala703^{6,54}; GABA_{B2}: Tyr564^{3,40}, Tyr661^{5,44}, and Ala707^{6,54}), (3) 18-carbon fatty acyl chain (GABA_{B1b}: Ile724^{7,36}; GABA_{B2}: Ile728^{7,36}).

Extended Data Fig. 8 |. Endogenous phospholipid interactions with GABA_B receptor.

a,c,e, Orthogonal views of potential access channel in GABA_{B1b}, GABA_{B2}, and S1P₁ in molecular surface representation, along with phospholipids PE 38:5 and PC 38:2, as well as sphingolipid mimic ML056, respectively, in space-filling representation. Side view (left) shows opening between helices TM5 and TM6 in GABA_{B1b} (**a**) and GABA_{B2} (**c**), and between TM1 and TM7 in S1P₁ (**e**), while top view (right) highlights blocked entrance to lipid-binding pocket from the extracellular side. In all cases, ECL1 and ECL3 (orange), ECL2 (pale brown), as well as the linker of GABA_B receptor subunits (purple) and N-terminal helix of S1P₁ (purple) are distinguished by color.

b,d,f, The same information presented in (**a**, **c**, **e**) but with ribbon model used for GABA_{B1b} (**b**), GABA_{B2} (**d**), and S1P₁ (**f**). Lipids are in stick model.

g,h, Functional effect of a GABA_{B2} lipid-binding site mutation. Basal activity (**g**) and dose-dependent baclofen-stimulated receptor response (**h**) in cells transiently expressing Gα_{q15}

(abbreviated as Gqi) with WT GABA_B receptor or WT GABA_{B1b} and mutant GABA_{B2}-R714A (abbreviated as R714A) heterodimer. Cells transfected with Gα_{q15} alone were used as negative control. Relative activity in both graphs was measured by IP₁ accumulation, and expressed as percentage of maximum wild-type activity induced by baclofen relative to the activity of Gα_{q15} alone. Data points represent average ± s.e.m. of multiple experiments (n), each with quadruplicate measurements. ***P* = 0.0016, one-way ANOVA with Bonferroni's post hoc test was used to calculate statistical difference in basal activity (g). Cell surface expression level was 77% for the WT/R714A mutant in comparison with the WT/WT heterodimer.

Extended Data Fig. 9 | Comparison of GABA_B TM domain with other GPCRs.

- a**, Superposition of GABA_{B1b} and GABA_{B2} subunits based on their VFT modules. Purple line denotes the axis of rotation that relates the linker and TM domains of GABA_{B1b} and GABA_{B2} (rotation $\chi = 23^\circ$, screw translation $\tau_\chi = 0.01 \text{ \AA}$).
- b**, Superposition of the linker and TM domains of GABA_{B1b} and GABA_{B2} subunits.
- c**, Superposition of the linker and TM domains of each GABA_B subunit with class C GPCR mGlu₅²⁰ (PDB code: 6N52) in three different views, with arrows revealing inward extracellular shifts in TM5 and 7, as well as an inward intracellular shift in TM3, in mGlu₅ compared to either GABA_B subunit.
- d-f**, Superposition of the TM helices of each GABA_B subunit with the class A GPCR rhodopsin²⁷ (PDB code: 1F88) (**d**), class B GPCR CRF₁⁵⁷ (PDB code: 4K5Y) (**e**), and class F GPCR smoothened⁵⁸ (PDB code: 4JKV) (**f**). Arrows indicate large shifts in TM helix positions between GABA_B subunits and other GPCRs, such as outward extracellular movements in class A (TM2 and 6), class B (TM1, 2, and 7), and class F (TM2, 4, and 5). There are also inward intracellular shifts in TM7 in all comparisons, and outward intracellular shifts in TM5 in class A, B and F.

Extended Data Fig. 10 | Conserved motifs in GABA_B, rhodopsin and mGlu receptors.

a,b, The 'ionic lock' and FxPKxx motifs in GABA_{B1b} (**a**) and GABA_{B2} (**b**) subunits. The 'ionic locks' consist of Asp684 of ICL3 and Lys567^{3,50} in GABA_{B1b} and Asp688 of ICL3

and Lys574^{3,50} in GABA_{B2}. The FxPKxx motifs include the conserved Lys739^{7,51} of GABA_{B1b} and Lys743^{7,51} of GABA_{B2}, which interact with the 'ionic locks' through Asn^{2,39} (GABA_{B1b}-N513^{2,39}; GABA_{B2}-N520^{2,39}) and a serine (GABA_{B1b}-S508; GABA_{B2}-S515) in ICL1.

c, The 'ionic lock' and NPxxY motifs in class A rhodopsin²⁷.

d,e, The 'ionic lock' and FxPKxY motifs in class C receptors mGlu₁²⁹ (d) and mGlu₅²⁸ (e), which are in close proximity as in GABA_B subunits.

Key residues of the motifs are displayed in stick models. Hydrogen bonds are indicated by black dotted lines. Interactions between participating residues of the 'ionic lock' are denoted by red dotted lines with distances labeled. Distances between the Ca atoms of the 'ionic lock' residues are marked by brown dotted lines.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments:

We thank Dr. Richard Henderson for early-stage cryo-EM investigation and critical reading of the manuscript, Dr. Charles S. Zuker for advice and financial support, Dr. Charles Karan and Ronald Realubit for assistance with the EnVision plate reader at Columbia Genome Center, Drs. Alexander Sobolevsky, Kei Saotome, and Erhu Cao for the gift of BacMam vectors, Dr. Yung H. Wong for the plasmid of a Gα_q5 chimera, Drs. Brian K. Kobilka and Georgios Skiniotis for advice. Titan Krios data collection was performed at the Simons Electron Microscopy Center, directed by Dr. Bridget O. Carragher and Clint Potter, supported by grants from the Simons Foundation (SF349247), NYSTAR, and NIH (GM103310). This work was supported by NIH grants R01GM088454 (to Q.R.F.), R01GM125801 (to Q.R.F., P.A.S., M.Q.), R01GM107462 (to W.A.H.), P41GM116799 (to W.A.H.), and U2C ES030158 for lipid identification (to O.F.). Q.R.F. was an Irma Hirschl Career Scientist, Pew Scholar, McKnight Scholar and Schaefer Scholar.

References

1. Bettler B, Kaupmann K, Mosbacher J & Gassmann M Molecular structure and physiological functions of GABA(B) receptors. *Physiol. Rev* 84, 835–867, (2004). [PubMed: 15269338]
2. Jones KA et al. GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. *Nature* 396, 674–679, (1998). [PubMed: 9872315]
3. Kaupmann K et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. *Nature* 396, 683–687, (1998). [PubMed: 9872317]
4. White JH et al. Heterodimerization is required for the formation of a functional GABA(B) receptor. *Nature* 396, 679–682, (1998). [PubMed: 9872316]
5. Kuner R et al. Role of heteromer formation in GABA_B receptor function. *Science* 283, 74–77, (1999). [PubMed: 9872744]
6. Ng GY et al. Identification of a GABA_B receptor subunit, gb2, required for functional GABA_B receptor activity. *J. Biol. Chem* 274, 7607–7610, (1999). [PubMed: 10075644]
7. Kaupmann K et al. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. *Nature* 386, 239–246, (1997). [PubMed: 9069281]
8. Malitschek B et al. The N-terminal domain of gamma-aminobutyric Acid(B) receptors is sufficient to specify agonist and antagonist binding. *Mol. Pharmacol* 56, 448–454, (1999). [PubMed: 10419566]
9. Galvez T et al. Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. *EMBO J.* 20, 2152–2159, (2001). [PubMed: 11331581]
10. Margeta-Mitrovic M, Jan YN & Jan LY Function of GB1 and GB2 subunits in G protein coupling of GABA(B) receptors. *Proc. Natl. Acad. Sci. U. S. A* 98, 14649–14654, (2001). [PubMed: 11724956]

11. Robbins MJ et al. GABA(B2) is essential for g-protein coupling of the GABA(B) receptor heterodimer. *J. Neurosci* 21, 8043–8052, (2001). [PubMed: 11588177]
12. Duthey B et al. A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. *J. Biol. Chem* 277, 3236–3241, (2002). [PubMed: 11711539]
13. Havlickova M et al. The intracellular loops of the GB2 subunit are crucial for G-protein coupling of the heteromeric gamma-aminobutyrate B receptor. *Mol. Pharmacol* 62, 343–350, (2002). [PubMed: 12130687]
14. Monnier C et al. Trans-activation between 7TM domains: implication in heterodimeric GABA(B) receptor activation. *EMBO J.* 30, 32–42, (2011). [PubMed: 21063387]
15. Pin JP & Bettler B Organization and functions of mGlu and GABAB receptor complexes. *Nature* 540, 60–68, (2016). [PubMed: 27905440]
16. Geng Y, Bush M, Mosyak L, Wang F & Fan QR Structural mechanism of ligand activation in human GABA(B) receptor. *Nature* 504, 254–259, (2013). [PubMed: 24305054]
17. Burmakina S, Geng Y, Chen Y & Fan QR Heterodimeric coiled-coil interactions of human GABAB receptor. *Proc. Natl. Acad. Sci. U. S. A* 111, 6958–6963, (2014). [PubMed: 24778228]
18. Conklin BR, Farfel Z, Lustig KD, Julius D & Bourne HR Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. *Nature* 363, 274–276, (1993). [PubMed: 8387644]
19. Xue L et al. Rearrangement of the transmembrane domain interfaces associated with the activation of a GPCR hetero-oligomer. *Nat Commun* 10, 2765, (2019). [PubMed: 31235691]
20. Koehl A et al. Structural insights into the activation of metabotropic glutamate receptors. *Nature* 566, 79–84, (2019). [PubMed: 30675062]
21. Geng Y et al. Structural mechanism of ligand activation in human calcium-sensing receptor. *Elife* 5, (2016).
22. Galvez T et al. Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. *Mol. Pharmacol* 57, 419–426, (2000). [PubMed: 10692480]
23. Wise A et al. Calcium sensing properties of the GABA(B) receptor. *Neuropharmacology* 38, 1647–1656, (1999). [PubMed: 10587080]
24. Hanson MA et al. Crystal structure of a lipid G protein-coupled receptor. *Science* 335, 851–855, (2012). [PubMed: 22344443]
25. Rasmussen SG et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature* 477, 549–555, (2011). [PubMed: 21772288]
26. Thal DM, Glukhova A, Sexton PM & Christopoulos A Structural insights into G-protein-coupled receptor allostery. *Nature* 559, 45–53, (2018). [PubMed: 29973731]
27. Palczewski K et al. Crystal structure of rhodopsin: A G protein-coupled receptor. *Science* 289, 739–745, (2000). [PubMed: 10926528]
28. Dore AS et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. *Nature* 511, 557–562, (2014). [PubMed: 25042998]
29. Wu H et al. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. *Science* 344, 58–64, (2014). [PubMed: 24603153]

Methods references

30. Goehring A et al. Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. *Nat. Protoc* 9, 2574–2585, (2014). [PubMed: 25299155]
31. Margeta-Mitrovic M, Jan YN & Jan LY A trafficking checkpoint controls GABA(B) receptor heterodimerization. *Neuron* 27, 97–106, (2000). [PubMed: 10939334]
32. Pagano A et al. C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(b) receptors. *J. Neurosci* 21, 1189–1202, (2001). [PubMed: 11160389]
33. Reeves PJ, Callewaert N, Contreras R & Khorana HG Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-

- inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. *Proc. Natl. Acad. Sci. U. S. A* 99, 13419–13424, (2002). [PubMed: 12370423]
34. Zheng SQ et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* 14, 331–332, (2017). [PubMed: 28250466]
 35. Scheres SH RELION: implementation of a Bayesian approach to cryo-EM structure determination. *J. Struct. Biol* 180, 519–530, (2012). [PubMed: 23000701]
 36. Zhang K Gctf: Real-time CTF determination and correction. *J. Struct. Biol* 193, 1–12, (2016). [PubMed: 26592709]
 37. Punjani A, Rubinstein JL, Fleet DJ & Brubaker MA cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat Methods* 14, 290–296, (2017). [PubMed: 28165473]
 38. Scheres SH & Chen S Prevention of overfitting in cryo-EM structure determination. *Nat Methods* 9, 853–854, (2012). [PubMed: 22842542]
 39. Tan YZ et al. Addressing preferred specimen orientation in single-particle cryo-EM through tilting. *Nat Methods* 14, 793–796, (2017). [PubMed: 28671674]
 40. Pettersen EF et al. UCSF Chimera--a visualization system for exploratory research and analysis. *J. Comput. Chem* 25, 1605–1612, (2004). [PubMed: 15264254]
 41. Punjani A & Fleet DJ 3D Variability Analysis: Directly resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM images. *bioRxiv*, (2020).
 42. Emsley P, Lohkamp B, Scott WG & Cowtan K Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr* 66, 486–501, (2010). [PubMed: 20383002]
 43. Adams PD et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr* 66, 213–221, (2010). [PubMed: 20124702]
 44. Chen VB et al. MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr. D Biol. Crystallogr* 66, 12–21, (2010). [PubMed: 20057044]
 45. Barad BA et al. EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy. *Nat Methods* 12, 943–946, (2015). [PubMed: 26280328]
 46. Novotny M, Madsen D & Kleywegt GJ Evaluation of protein fold comparison servers. *Proteins* 54, 260–270, (2004). [PubMed: 14696188]
 47. Goddard TD et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci.* 27, 14–25, (2018). [PubMed: 28710774]
 48. Morin A et al. Collaboration gets the most out of software. *Elife* 2, e01456, (2013). [PubMed: 24040512]
 49. Geng Y et al. Structure and functional interaction of the extracellular domain of human GABA(B) receptor GBR2. *Nat. Neurosci* 15, 970–978, (2012). [PubMed: 22660477]
 50. Quick M & Javitch JA Monitoring the function of membrane transport proteins in detergent-solubilized form. *Proc. Natl. Acad. Sci. U. S. A* 104, 3603–3608, (2007). [PubMed: 17360689]
 51. Gupta K et al. Identifying key membrane protein lipid interactions using mass spectrometry. *Nat. Protoc* 13, 1106–1120, (2018). [PubMed: 29700483]
 52. Mafu S et al. Biosynthesis of the microtubule-destabilizing diterpene pseudolaric acid B from golden larch involves an unusual diterpene synthase. *Proc. Natl. Acad. Sci. U. S. A* 114, 974–979, (2017). [PubMed: 28096378]
 53. Kind T et al. LipidBlast in silico tandem mass spectrometry database for lipid identification. *Nat Methods* 10, 755–758, (2013). [PubMed: 23817071]
 54. Mukherjee RS, McBride EW, Beinborn M, Dunlap K & Kopin AS Point mutations in either subunit of the GABAB receptor confer constitutive activity to the heterodimer. *Mol. Pharmacol* 70, 1406–1413, (2006). [PubMed: 16847143]
 55. Chen KLB, Amarasiriwardena CJ & Christiani DC Determination of total arsenic concentrations in nails by inductively coupled plasma mass spectrometry.. *Biol. Trace Elem. Res* 67, 109–125, (1999). [PubMed: 10073418]
 56. Pruszkowski E, Neubauer K & Thomas R An Overview of Clinical Applications by Inductively Coupled Plasma Mass Spectrometry.. *At. Spectrosc* 19, 111–115, (1998).

57. Hollenstein K et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. *Nature* 499, 438–443, (2013). [PubMed: 23863939]
58. Wang C et al. Structure of the human smoothened receptor bound to an antitumour agent. *Nature* 497, 338–343, (2013). [PubMed: 23636324]

Fig. 1 |. Cryo-EM structure of human GABA_B receptor.

a, Ribbon representation of GABA_B receptor structure composed of GABA_{B1b} (blue) and GABA_{B2} (green) subunits. Ca²⁺ (green): sphere. Phospholipids (PE 38:5; PC 38:2; yellow): space-filling models. N-linked glycans (NAG, gray) and cholesterol (CLR, pink): ball-and-stick models. TM helices 1 through 7 are marked for each subunit.

b, Cryo-EM density map of GABA_B receptor composed of local reconstructions for extracellular (3.1 Å) and TM (3.4 Å) domains, in an orthogonal view from (a).

c, Linker domains of GABA_{B1b} and GABA_{B2}, showing the main-chain and side-chain hydrogen-bonding patterns between linker region and ECL2.

Fig. 2 |. Transmembrane heterodimer interface of GABA_B receptor.

a, TM heterodimer interface formed by TM5 and TM3 of both subunits. Three layers (I, II, III) of interfacial contacts are identified by dotted circles. Direct heterodimer contacts within each layer are displayed in panels on the right.

b,c, Functional analysis of the 'intersubunit latch'. Basal activity (**b**) and dose-dependent baclofen-stimulated receptor response (**c**) in cells transiently expressing the Gα_{q15} chimera protein (abbreviated as Gqi) with different combinations of wild-type (WT) and mutant GABA_B subunits (GABA_B1b-E673R, abbreviated as E673R; GABA_B2-H579E, abbreviated as H579E). IP₁ accumulation was measured in the presence and absence of 20 μM CGP54626 (abbreviated as INV). Cells transfected with empty pcDNA3.1 vector, Gα_{q15} alone, or WT GABA_B subunits in the absence of Gα_{q15} were used as controls. Relative activity is expressed as percentage of maximum wild-type activity induced by baclofen relative to the activity of Gα_{q15} alone. Data points represent average ± s.e.m. of multiple experiments (n), each with quadruplicate measurements. ****P < 0.0001, one-way ANOVA with Bonferroni's post hoc test was used to calculate statistical differences in basal activity (**b**). Cell surface expression level was 90% for the E673R/WT and 76% for WT/H579E mutants in comparison with the WT/WT heterodimer.

Fig. 3 |. Ca²⁺ binding in GABA_{B1b}.

a, Ribbon representation of GABA_{B1b} subunit showing the location of Ca²⁺-binding site at the interdomain crevice of VFT.

b, Specific interactions between GABA_{B1b} and Ca²⁺. Mesh represents the cryo-EM density map contoured at 7.5 σ surrounding Ca²⁺.

c, CaS receptor ECD crystal structure (PDB code: 5K5S) highlighting its bound Ca²⁺ (black spheres, numbered 1–4 and 1'–4' in the two protomers) and the corresponding location of the Ca²⁺-binding site in GABA_{B1b} (green sphere).

Fig. 4 |. Identification of endogenous phospholipid ligands of GABA_B receptor.

a,c, LC-MS/MS analysis of phospholipids bound to GABA_B receptor (n=1). LC traces showing the abundance of PC 38:2 (**a**) and PE 38:5 (**c**) lipids in GABA_B preparation relative to a CaS receptor control.

b,d, High-resolution MS spectra of the peaks in (**a**, **c**) (black) matched with standard spectra of PC 38:2 (**b**) and PE 38:5 (**d**) in red.

e,f, Molecular surface of GABA_{B1b} (**e**) and GABA_{B2} (**f**) TM domain showing the binding pocket for PE 38:5 and PC38:2, respectively.

g-j, Three views of the specific interactions between phospholipid and each GABA_B subunit. Contacts are shown between the phospholipid head group and residues from GABA_{B1b} (**g**) and GABA_{B2} (**h**), as well as phospholipid fatty acyl chains and GABA_{B1b} (**i**) and GABA_{B2} (**j**).